Which company produces Cabozantinib? Is it an original drug?

Cabozantinib is an oral, small molecule, multi-target tyrosine kinase inhibitor that is widely used to treat a variety of cancers, including renal cell carcinoma, medullary thyroid carcinoma, and hepatocellular carcinoma. The drug exerts anti-tumor effects by inhibiting multiple signaling pathways including MET, VEGFR and AXL, blocking tumor angiogenesis and cell proliferation.

The original drug of cabozantinib was developed by the American company Exelixis and cooperated with Pfizer (Pfizer) for marketing. ExelixisAs the original developer, it has the patent rights and exclusive sales rights of the drug. The original drug is sold in many countries and regions under the trade name "Cabometyx". Pfizer is responsible for the commercial operations and supply of the drug in multiple markets around the world, ensuring that patients can obtain high-quality drugs through formal channels.

Currently, cabozantinib, as the original drug, has been approved by the US FDA, EU EMA, China State Food and Drug Administration and other countries and regions for the treatment of related cancers. The research and development background and rigorous clinical trial data of the original drug provide a solid guarantee for its efficacy and safety, so it is highly recognized by clinicians and patients.

As patents gradually expire, generic cabozantinib drugs produced in many countries have appeared on the market. These generic drugs are usually more affordable, increasing drug accessibility for patients. However, original drugs still maintain a leading position in terms of therapeutic effect, quality control and drug stability. Patients should consider the cost-effectiveness and treatment needs of the drug based on the doctor's advice when choosing.

Reference materials:https://www.drugs.com/